Targeting tumor vasculature with TNF leads effector T cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with …

AR Elia, M Grioni, V Basso, F Curnis, M Freschi… - Clinical Cancer …, 2018 - AACR
Purpose: Irregular blood flow and endothelial cell anergy, which characterize many solid
tumors, hinder tumor infiltration by cytotoxic T lymphocytes (CTL). This confers resistance to …
被引用次数：52 相关文章

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with …

AR Elia, M Grioni, V Basso, F Curnis… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose: Irregular blood flow and endothelial cell anergy, which characterize many solid
tumors, hinder tumor infiltration by cytotoxic T lymphocytes (CTL). This confers resistance to …

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with …

AR Elia, M Grioni, V Basso, F Curnis… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: Irregular blood flow and endothelial cell anergy, which characterize many solid
tumors, hinder tumor infiltration by cytotoxic T lymphocytes (CTL). This confers resistance to …

Targeting tumor vasculature with TNF leads effector t cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with adoptive …

AR Elia, M Grioni, V Basso, F Curnis, M Freschi… - CLINICAL CANCER …, 2018 - iris.unisr.it
Purpose: Irregular blood flow and endothelial cell anergy, which characterize many solid
tumors, hinder tumor infiltration by cytotoxic T lymphocytes (CTL). This confers resistance to …